Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT03235245	Phase II	Binimetinib + Encorafenib Ipilimumab + Nivolumab	Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)	Active, not recruiting	POL \| NLD \| ITA \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU	0
NCT04551521	Phase II	Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib	CRAFT: The NCT-PMO-1602 Phase II Trial	Recruiting	DEU	0
NCT02130466	Phase Ib/II	Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib	A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)	Completed		0
NCT03898908	Phase II	Binimetinib + Encorafenib	Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)	Active, not recruiting	ESP	0
NCT03973918	Phase II	Binimetinib + Encorafenib	Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)	Terminated	USA	0
NCT03915951	Phase II	Binimetinib + Encorafenib	An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer	Active, not recruiting	USA \| NLD \| ITA \| ESP	1
NCT03839342	Phase II	Binimetinib + Encorafenib	Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)	Active, not recruiting	CAN	0
NCT03975231	Phase I	Dabrafenib + Trametinib	Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer	Recruiting	USA	0
NCT05270044	Phase III	Binimetinib + Encorafenib	Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)	Active, not recruiting	SWE \| ROU \| POL \| NOR \| NLD \| ITA \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BEL \| AUT \| AUS \| ARG	3
NCT06007924	Phase II	Defactinib + RO5126766	A Study of Avutometinib and Defactinib in People With Thyroid Cancer	Recruiting	USA	0
NCT05203172	FDA approved	Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib	The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials	Recruiting	USA \| SVK \| NLD \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| AUS	4
NCT03878719	Phase I	Binimetinib + Encorafenib	Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma	Terminated	ITA	0
NCT02693535	Phase II	Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)	Recruiting	USA	0
NCT04201457	Phase Ib/II	Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib	A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration	Recruiting	USA	0
NCT06194929	Phase Ib/II	Defactinib + Encorafenib + RO5126766 Defactinib + RO5126766	Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)	Recruiting	USA	0
NCT04557956	Phase Ib/II	Tazemetostat Dabrafenib + Tazemetostat + Trametinib	Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	Recruiting	USA	0
NCT03864042	Phase I	Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib	Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors	Completed	USA \| NLD \| ESP \| CAN \| BEL	0
NCT05097378	Phase II	Binimetinib + Encorafenib	Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)	Unknown status	GBR	0
NCT04310397	Phase II	Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib	Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma	Terminated	USA	0
NCT02465060	Phase II	Nivolumab + Relatlimab Dabrafenib + Trametinib	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Active, not recruiting	USA	2
NCT04074096	Phase II	Binimetinib + Encorafenib + Pembrolizumab	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)	Active, not recruiting	FRA	0
NCT04657991	Phase III	Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab	A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma	Active, not recruiting	USA \| TUR \| SVK \| POL \| NZL \| NOR \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| FIN \| ESP \| DEU \| CZE \| CHE \| CAN \| BRA \| BGR \| BEL \| AUT \| ARG	4
NCT02257424	Phase Ib/II	Dabrafenib + Hydroxychloroquine + Trametinib	Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)	Completed	USA	0
NCT05926960	Phase II	Binimetinib + Encorafenib + Pembrolizumab Ipilimumab + Nivolumab	A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)	Active, not recruiting	SVK \| POL \| ITA \| GBR \| ESP \| DEU \| CZE	0
NCT04759846	Phase I	Binimetinib + Encorafenib	Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma	Withdrawn	ITA \| ESP \| CZE	0
NCT01659151	Phase II	Aldesleukin Fludarabine Vemurafenib	Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma	Active, not recruiting	USA	0

Profile Name	BRAF V600K
Gene Variant Detail	BRAF V600K (gain of function)
Relevant Treatment Approaches	BRAF Inhibitor MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RAF Inhibitor (Pan)

Molecular Profile Detail

Contact

Filtering

Sorting